Effectiveness and potential drug interactions in antiviral therapy for the treatment of chronic hepatitis C
real-life data from a specialized center in southern Brazil
DOI:
https://doi.org/10.1590/s2175-9790201900041874Keywords:
Hepatitis C; Drug interactions; Direct-acting antivirals; Safety; Real-world dataAbstract
Direct-acting antivirals used in the treatment of hepatitis C have demonstrated high rates of efficacy, are well tolerated and considered safe. However, they are not free of drug interactions. To describe the effectiveness of hepatitis C treatment and the incidence and severity of potential drug interactions between drugs used during this treatment. A cross-sectional study with 148 patients who began treatment for hepatitis C between April and June 2016 in a specialized center in Brazil. Drug interactions were identified in the Truven Health Analytic/DynaMed Plus and Hep-C Interactions databases. Regarding treatment outcome, 93.9% of patients achieved SVR, 2.7% relapsed and 3.4% did not return after the end of the follow-up period. A total of 328 chronic diseases were identified (71 different diseases), and 88.5% of the patients had at least one chronic disease. The patients reported the use of 474 drugs (121 different drugs), with 3.2 drugs per patient on average. We identified 265 potential drug interactions, classified as important (6.0%), with clinical significance (20.7%) and without clinical significance or with insufficient data (69.4%). Cirrhotic patients had a higher average number of potential drug interactions than non-cirrhotic patients (2.51 x 0.79, p = 0.000). Hepatitis C treatment with direct-acting antivirals are effective and safe for most of patients.
Downloads
References
Arrais PSD, Fernandes MEP, Pizzol T da SD, Ramos LR, Mengue SS, Luiza VL, et al. Prevalence of self-medication in Brazil and associated factors. Rev Saúde Pública. 2016;50(Suppl 2):13s.
Bansall S, Singal AK, Mcguire BM, Anand BS. Impact of all anti-hepatitis C virus therapy: a meta-analysis. World J of Hepatol. 2015;7(5):806-813.
Binda C, Tortora A, Garcovich M, Annichiarico BE, Siciliano M. Toxicity and risks from drugdrug interactions of new antivirals for chronic hepatitis C. Eur Rev Med Pharmacol Sci. 2017;21(Suppl 1):102-111.
Brasil. Ministério da Saúde. Conitec. Relatório de recomendação. Protocolo clínico e diretrizes terapêuticas para a hepatite C e coinfecções. No. 171, julho de 2015.
Bristol-Myers Squibb Farmacêutica Ltda. Daklinza (Daclatasvir) comprimidos revestidos 30 e 60 mg. Bula do profissional da saúde; 2015.
Castro R, Perazzo H, Grinsztejn B, Veloso VG, Hyde C. Chronic hepatitis C: an overview of evidence on epidemiology and management from a Brazilian perspective. Int J Hepatol. 2015;2015:852968.
Classificação Estatística Internacional de Doenças e Problemas Relacionados à Saúde-10ª. Revisão (Cid 10). Cited 2018 Jan 13 . Available from: http://www.datasus.gov.br/cid10/V2008/cid10.htm
» http://www.datasus.gov.br/cid10/V2008/cid10.htm
eming P, Martin MT, Chan J, Dilworth TJ, El-Lababidi R, Love BL, et al. Therapeutic advances in HCV genotype 1 infection: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2016;36(2):203-217.
Farmanguinhos Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Ribavirina Cápsulas 250 mg. Bula do profissional da saúde; 2017.
lisiak R, Pogorzelska J, Flisiak-Jackiewicz M. Hepatitis C: efficacy and safety in real life Liver Int. 2017;37(Suppl 1):
Gilead Sciences Farmacêutica do Brasil Ltda. Sovaldi (Sofosbuvir) comprimidos revestidos 400 mg. Bula do profissional da saúde; 2015.
HEP Drug Interactions. University of Liverpool. Cited 2018 Jan 20 . Available from: https://www.hep-druginteractions.org/checker
» https://www.hep-druginteractions.org/checker
Janssen-Cilag Farmacêutica Ltda. Olysio (Simeprevir sódico) cápsulas duras 150 mg. Bula do profissional da saúde; 2015.
Kolor, B. Patient education and treatment strategies implemented at a pharmacist- manages hepatitis C virus clinic. Pharmacoterapy. 2005;25(9);1230-1241.
Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, et al. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferonfree DAAs in the PITER Cohort Study. PLoS One. 2017;12(2):e0172159.
Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification anmanagement of drug drug interactions World J Gastroenterol. 2017;23(9):1618-1626.
Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther. 2013;37(12):1132-56.
Li DK, Yan P, Abou-Samra A-B, Chung RT, Butt AA. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES. Aliment Pharmacol Ther. 2018;47(2):246-58.
Melo DO, Storpirtis S, Ribeiro E. Does hospital admission provide an opportunity for improving pharmacotherapy among elderly inpatients? Braz J Pharm Sci. 2016;52(3):391-401.
Mesquita F, Santos ME, Benzaken A, Corrêa RG, Cattapan E, Sereno LS, et al. The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy. BMC Public Health. 2016;16:1132.
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1)77-87.
Mohammad RA, Bulloch MN, Chan J, Deming P, Love B, Smith L, et al. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection. Pharmacotherapy. 2014;34(12):1341-1354.
Ottman AA, Townsend ML, Hashem MG, DiMondi VP, Britt RB. Incidence of drug interactions identified by clinical pharmacists in veterans initiating treatment for chronic hepatitis C infection. Ann Pharmacother. 2018;52(8):763-768.
Pons ST, Boyer A, Lamblin G, Chennell P, Châtenet FT, Nicolas C, et al. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol. 2017;83(2):269-293.
Pinto MCX, Malaquias DP, Ferré F, Pinheiro MLP. Potentially inappropriate medication use among institutionalized elderly individuals in southeastern Brazil. Braz J Pharm Sci. 2013;49(4):709-717.
Scavone C, Sportiello L, Rafaniello C, Mascolo A, Sessa M, Rossi F, et al. New era in treatment options of chronic hepatitis C: focus on safety of new direct acting antivirals (DAAs). Expert Opin On Drug Saf. 2016;15(S2):85-10.
Sette-Jr H, Cheinquer H, Wolff FH, de Araujo A, Coelho-Borges S, Soares SRP, et al. Treatment of chronic HCV infection with the new direct acting antivirals (DAA): first report of a real world experience in southern Brazil. Ann Hepatol. 2017;16(5):727-733.
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211-221
Teotonio RA, Stahlschmidt R, Granja S, Pilger D, Falcão ALE, Mazzola PG. Prevalence of potential drug-drug interactions in the intensive care unit of a Brazilian teaching hospital. Braz J Pharm Sci. 2017;53(1):e16109.
Truven Health Analytics. DynaMed Plus Internet . Ipswich (MA): EBSCO Information Services. 1995 -. Record No. 906021, Sofosbuvir; updated 2017 Mar 31, Porto Alegre ; Available from http://www.dynamed.com/login.aspx?direct=true&site=DynaMed&id=906021 Registration and login required.
» http://www.dynamed.com/login.aspx?direct=true&site=DynaMed&id=906021
Umar M, Akhter TS, Osama M. Issues pertaining to daas. Short Communication. J Ayub Med Coll Abbottabad. 2016;28(4 Suppl 1):895-900.
Walters-Smith N, Marshall SR. Opportunities and considerations for pharmacist intervention in the management of the chronic hepatitis C patient. Letter. J Manag Care Pharm. 2009;15(5):417-419.
Weersink RA, Bouma M, Burger DM, Drenth JPH, Hunfeld NGM, Kranenborg M, et al. Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. BMJ Open. 2016;6(10):e012991.
WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2018. Cited 2018 Jan 13 . Available from: http://www.whocc.no/atc_ddd_index/
» http://www.whocc.no/atc_ddd_index/
World Health Organization (WHO), 2017. Hepatitis C key facts, Fact sheet no. 164, World Health Organization Media Centre, Geneva, Switzerland, 2017. cited 2018 Mar 10 . Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
